🔗 Share this article

While America proceeds with historic revisions to its vaccine guidelines, a particular individual appears unexpectedly: Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by expressing skepticism about Covid vaccines in the pandemic and has focused upon potential deaths after Covid vaccination in her short position at the FDA.

Scheduled Changes to Childhood Vaccine Schedule

Public health authorities planned to announce radical changes to the childhood immunization program in December, aligning the US with Denmark’s immunization schedule, according to reports – a significant shift that would place the US out of step with many the world with little proof for benefit. This reveal has been postponed until the new year.

Instead of Vinay Prasad, Høeg is set to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth person to run the center this year.

A New Direction at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for ending some pediatric shot schedules in the US so as to align more similar to Denmark's approach, a country with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

In her initial statements, she has continued to focus on immunizations – traditionally the purview of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Concerns Over Background

The appointee has no apparent experience in pharmaceutical research, approval processes or administrative roles, which has been customary for past heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and the vaccine center since spring.

“She appears not to have any of the qualifications” for running the CDER, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Past commissioners of CBER would “understand regulatory frameworks and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”

CDER has an enormous range of responsibilities at the agency, Woodcock stated.

“Everybody just pays attention on the new drug program, but the generic program authorizes thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and more, and all of those must be supervised,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

There is also, a substantial management aspect to the job, which supervises over 5,000 employees. “It is a huge management job, if you perform it correctly,” she concluded.

Agency Reaction and Controversial Programs

In response to concerns about Dr. Høeg's qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a representative stated that the “inquiries are based on incorrect assumptions”.

“This background aligns with the functions of her role,” the representative said, citing the period Høeg spent counseling the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious expedited therapy clearance system that apparently troubled her former heads. “By what process are these drugs being selected for this voucher program? Who makes the calls?” Howard said. “There’s a lot of secrecy going on at the agency right now.”

In general, he said, “the agency looks to be trending towards laxer regulations of pharmaceuticals, except for vaccines.”

Established Track Record on Vaccines

With vaccines, Høeg has a more documented, if problematic, past, critics said. She authored a research paper using non-validated crowd-sourced reports to estimate the rate of heart inflammation after COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccines are riskier than they are.

Included in her “policy goals” for the new federal leadership featured changing rules for recently developed shots and ending “optional” vaccines, she stated post-election on a audio program. At the FDA, Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She’s an complete dogmatist who starts off with her preconceived notions and reverse-engineers to retrofit the science in a highly deceptive, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg became part of fellow dissenters, {like|